As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining ...

Global Blood Therapeutics had developed Oxbryta that was used to treat haemolytic anaemia (excess breakdown of red blood cells) in patients aged 12 years and older who have sickle cell disease.

Oxbryta is manufactured as an oral therapy for patients with sickle cell disease. Hardiman began taking Oxbryta in 2020 under the belief that it would help manage his sickle cell disease.

Sickle cell disease summit hosted by HHS highlights advancements and challenges. Learn about the summit and the experiences ...

The hemoglobin elevating agent is being developed for the treatment of anemia associated with multiple diseases.

Newborn screening, comprehensive care, and disease-modifying therapies are changing the outlook for patients with sickle cell ...

Topline Data from 52-week Phase 3 Study Expected in Late 2025 –CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, ...

The "Sickle Cell Disease Market Assessment: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access" report has been added to ResearchAndMarkets.com's offering. The ...

Editas Medicine (EDIT) announced its achievement of in vivo preclinical proof of concept of hematopoietic stem and progenitor cell, HSPC, ...

Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET. Company Participants. Chris Taylor - Vice President, Investor Relations and ...